GENECENTRIC THERAPEUTICS, INC.

CSP

Diagnostic kits comprised of medical diagnostic reagents and assays for testing body fluids and tissues; Diagnostic kits comprised of medical diagnostic reagents and assays for use in connection with DNA sequencing and genetic analysis; Cell preparations, cellular vaccines and cellular biologics for the treatment of cancer; Diagnostic agents, preparations and substances for medical purposes;CANCER SUBTYPING PLATFORM;CANCER SUBTYPE PLATFORM;

GENECENTRIC

Assays for the medical diagnostic, prognostic and predictive testing of tumors; Medical diagnostic kits containing assays for the medical diagnostic, prognostic and predictive testing of tumors; Biological preparations for the treatment of cancer; Diagnostic preparations for medical purposes; Diagnostic kits comprised of diagnostic reagents and diagnostic assays for testing tissue samples for use in cancer detection, analysis and prognosis; Medical diagnostic reagents; Clinical diagnostic reagents for medical use; Diagnostic kits consisting primarily of enzymes, nucleic acids, buffers, reagents and assays for use in disease testing for medical purposes; Medical diagnostic assays for testing body fluids for medical and prognostic purposes; Medical diagnostic reagents and assays for testing tissue samples; Enzyme preparations for medical purposes; Biological preparations for the detection, diagnosis and monitoring of cancer;

GENECENTRIC

Providing medical, scientific and pharmaceutical research services; Providing medical research and scientific research information in the field of oncology; Providing medical and scientific research services in the field of cancer diagnosis, prognosis, therapy, prevention, treatment and patient management; Providing research and development services in the pharmaceutical and biotechnology fields; Research and development services in the field of gene expression, namely, cancer biology; Providing medical and scientific research services and information in the field of clinical trials; Research and development services for others, namely, research and development of assays for oncological testing, treatment and diagnostic purposes; Scientific research in the field of genome sequence analysis and reporting; Medical laboratory testing services; Providing genome sequencing, data analysis and interpretation, assay development and preparing, amplifying, labeling, detecting, analyzing and sequencing nucleic acids and other biological molecules, and research and design relating thereto, all in the field of bioinformatics, genomics and gene expression research and development;

GENECENTRIC

medical services; medical diagnostic testing, monitoring and reporting services; medical testing for diagnostic or treatment purposes in the field of cancer; providing patient medical record information and patient reports based thereon to physicians; providing information to physicians and patients regarding medical diagnostic tests that will help them make better health care decisions; medical information services; medical information services, namely, reporting of testing results directly to patients;

LSP

Assays for the medical diagnostic, prognostic and predictive testing of tumors; and medical diagnostic kits containing assays for the medical diagnostic, prognostic and predictive testing of tumors;LUNG SUBTYPE PLATFORM;

LSP

Medical diagnostic testing, monitoring and reporting services; Medical testing for diagnostic or treatment purposes in the field of cancer; providing patient medical record information to doctors; analyzing medical patient data and providing medical patient reports based thereon to physicians; communicating to physicians and patients, information on diagnostic tests that will help them make better health care decisions; medical information services, namely, reporting of testing results directly to patients;Providing medical, scientific and pharmaceutical research services; Providing medical research and scientific research information in the field of oncology; Providing medical and scientific research services in the field of cancer diagnosis, prognosis, therapy, prevention, treatment and patient management; Providing research and development service in the pharmaceutical and biotechnology fields; Research and development in the field of gene expression, namely, cancer biology; Providing medical and scientific research services and information in the field of clinical trials; Research and development services for others, namely, research and development of assays for oncological testing, treatment and diagnostic purposes; Scientific research in the field of genome sequence analysis and reporting; Medical laboratory testing services;

LSP

Assays for the medical diagnostic, prognostic and predictive testing of tumors; and medical diagnostic kits containing assays for the medical diagnostic, prognostic and predictive testing of tumors;

PURIST

Assays for the medical diagnostic, prognostic and predictive testing of tumors; diagnostic preparations for medical purposes; medical diagnostic reagents; medical diagnostic reagents and assays for testing tissue samples; biological preparations for the detection, diagnosis, subtyping and monitoring of cancer;Medical testing services; medical testing for diagnostic and treatment option purposes; medical services, namely, cell and gene therapy research; providing molecular genetics and genomics testing and reporting services in the field of biomarkers for the diagnosis, prognosis, treatment or management of cancer; providing a website and information in the field of medical research and scientific research in the fields of tumor biology, oncology, genetic therapy research, and diagnosis and treatment of cancers; provision of health care services, namely, providing oncological testing reports to physicians;Providing medical, scientific and pharmaceutical research services; providing medical research and scientific research information in the field of oncology; providing medical and scientific research services in the field of cancer diagnosis, prognosis, therapy, prevention, treatment and patient management; providing research and development services in the oncology; research and development in the field of RNA expression, namely, cancer biology; research and development services for others, namely, research and development of assays for oncological testing and diagnostic purposes; scientific research in the field of RNA expression analysis and reporting; providing laboratory research services in the field of pancreatic cancer; research and development in the fields of biomarker discovery and validation; medical and scientific research in the field of biomarker discovery in cancer patients; pharmaceutical and medical research in the field of survival outcomes and standard of care research; medical research featuring the identification and validation of cancer related biomarkers and RNA expression for use in improved patient outcomes;